In the structure of lung cancer incidence most cases belong to non-small cell lung cancer (NSCLC) which is subdivided into two histological subtypes: adenocarcinoma (AC) and squamous cell carcinoma (SCC). A five-year survival rate of patients with stage I NSCLC is two times higher than in patients with stage II and more than five times higher than in stages III-IV. Currently, there are no informative blood biomarkers to diagnose early stages of NSCLC. The aim of the study was to evaluate complex determination of hyaluronic acid (HA), CXCR2 and CXCR1 levels blood of patients with AC and SCC. Blood samples from of 107 patients with SCC, 90 patients with AC, and 40 healthy people were used in this study. Concentration of HA in blood serum was determined by enzyme linked immunoassay. The level of CXCR2 and CXCR1 was determined by flow cytometry. Diagnostic parameters were determined by constructing mathematical models in the form of regression equations using the method of stepwise inclusion of predictors and subsequent ROC-analysis. Results of the study indicate that MFI CXCR1 in granulocytes, proportion of lymphocytes containing CXCR2 and concentration of HA in blood serum in stage I AC and SCC are significantly higher than in healthy people. The level of these parameter significantly increases at stage II of the disease compared to stage I and demonstrates further growth at its later stages. Based on the obtained results, regression equations were created: (i) including MFI CXCR1 in granulocytes, proportion of lymphocytes supplied with CXCR2 and HA concentration in the serum to detect stages I-II SCC (diagnostic sensitivity — 95.7%, specificity — 93.7%, threshold value — 0.59) and stages III-IV SCC (diagnostic sensitivity — 93.1%, specificity — 93.3%, threshold value — 0.64); (ii) including the proportion of lymphocytes supplied with CXCR2 MFI CXCR1 in granulocytes and CYFRA 21-1 blood level, which allows the detection of I-II stages of AC (sensitivity — 91.3%, specificity — 94.7%, threshold value — 0.61); (iii) including the proportion of lymphocytes supplied with CXCR2 and CYFRA 21-1 blood level, which allows the detection of AC stages III-IV (sensitivity — 94.6%, specificity — 91.3%, threshold value — 0.15); (iv) including the proportion of lymphocytes supplied with CXCR2 and HA level in the serum to differentiate stage II SCC from stage I (sensitivity — 94.4%, specificity — 87.5%, threshold value — 0.44) and II stage AC from stage I (sensitivity — 88.5%, specificity — 91.2%, threshold value — 0.46).
Murashka D.I., Tahanovich A.D., Kauhanka M.M., Prokhorova V.I., Gotko O.V. (2021) Diagnostic efficiency of determining CXCR1, CXCR2 and hyaluronic acid blood level in non-small cell lung cancer patients. Biomeditsinskaya Khimiya, 67(5), 434-442.
Murashka D.I. et al. Diagnostic efficiency of determining CXCR1, CXCR2 and hyaluronic acid blood level in non-small cell lung cancer patients // Biomeditsinskaya Khimiya. - 2021. - V. 67. -N 5. - P. 434-442.
Murashka D.I. et al., "Diagnostic efficiency of determining CXCR1, CXCR2 and hyaluronic acid blood level in non-small cell lung cancer patients." Biomeditsinskaya Khimiya 67.5 (2021): 434-442.
Murashka, D. I., Tahanovich, A. D., Kauhanka, M. M., Prokhorova, V. I., Gotko, O. V. (2021). Diagnostic efficiency of determining CXCR1, CXCR2 and hyaluronic acid blood level in non-small cell lung cancer patients. Biomeditsinskaya Khimiya, 67(5), 434-442.
Rosen R.D., Sapra A. (2021) TNM Classification, StatPearls Publishing Internet. Scholar google search
Wang B.Y., Huang J.Y., Chen H.C., Lin C.H., Lin S.H., Hung W.H., Cheng Y.F. (2020) J. Cancer Res. Clin. Oncol., 146(1), 43-52. CrossRef Scholar google search
Liu Q., Li A., Tian Y., Wu J.D., Liu Y., Li T., Chen Y., Han X., Wu K. (2016) Cytokine Growth Factor Rev., 31, 61-71. CrossRef Scholar google search
Wang L., Shi L., Gu J., Zhan C., Xi J., Ding J., Ge D. (2018) J. Physiol. Biochem., 74(2), 313-324. CrossRef Scholar google search
Pirinen R., Tammi R., Tammi M., Hirvikoski P., Parkkinen J.J., Johansson R., Böhm J., Hollmén S., Kosma V.M. (2001) Int. J. Cancer, 95(1), 12-17. CrossRef Scholar google search
Rangel M.P., de Sá V.K., Martins V., Martins J.R.M., Parra E.R., Mendes A., Andrade P.S., Reis R.M., Longatto-Filho A., Oliveira C.Z., Takagaki T., Carraro D.M., Nader H.B., Capelozzi V.L. (2015) Braz. J. Med. Biol. Res., 48(6), 557-567. CrossRef Scholar google search
Lin W., Yugang L., Yuefeng M., Chao D., Huijun Z., Zhenghui L., Zhenning G., Changsheng Z. (2019) Cell Cycle, 18(24), 3456-3471. CrossRef Scholar google search
Rajul P., Mathai A., Shefali S., Chandra S., Ravi T. (2008) Indian J. Ophtalmol., 56(1), 45-50. CrossRef Scholar google search
Li X., Asmitananda T., Gao L., Gai D., Song Z., Zhang Y., Ren H., Yang T., Chen T., Chen M. (2012) Neoplasma, 59(5), 500-507. CrossRef Scholar google search
Hernandez-Hernandez J.R., Garcia-Garcia J.M., Martinez M.T. (1995) Int. J. Biol. Markers, 10(3), 149-155. Scholar google search
